





AVATAR

Accelerating Innovation through data sharing data with no privacy concerns

Project: CONCEPT/0722/0019



D1 Consortium Meeting Minutes

Date: 31/01/2024

Contents

1.	Intro	oduction	3			
1	.1	Purpose of the Document	3			
2.	Con	sortium meetings	3			
2	.1	Methodology	3			
2	.2	Meetings	3			
3.	Con	clusions	4			
4	Acknowledgement 4					

1. Introduction

AVATAR is a project led and coordinated by EUNDO LIMITED (EUN) and with partner the German Oncologoy Center (GOC). The nine (9) month project commences on 01/05/2023 and will be completed on 31/01/2024. The purpose of the project is to demonstrate the principle of generating synthetic healthcare data that mimic the statistical properties and attributes of real data. Although they mimic the real data, the synthetic data are not traceable to real data. Since they are not traceable to actual patients, privacy is preserved. The synthetic data can be used for training of healthcare professionals and also for training machine learning algorithms. So there is significant value to this data without compromising patient privacy.

The project is divided into four (4) work packages (WP) with WP1 devoted to the management and overseeing of the project, its objectives and deliverables. One of the main tools for effective management of the AVATAR was **consortium meetings**. The consortium meetings brought the whole team together to discuss progress and coordinate our activities.

The main objectives of work package (WP2) are to disseminate the knowledge, results, methodology and new techniques to scientists and engineers in the field of digital health. WP2 also informs the public and other stakeholders and innovators as a whole to generate interest in the project activities and results. Another important objective of WP2 is to secure subsequent private funding to: a) ensure the continuation of this project (to reach a higher TRL) and b) support the sustainable and continued collaboration between the partners.

1.1 Purpose of the Document

The purpose of this document is document the consortium meetings.

2. Consortium meetings

2.1 Methodology

To have effective meetings, the coordinator will ask for possible dates, times and mode (physical or virtual) and participation (there would be participation from both partners but depending on the topics different people could also be invited to participate and offer input). Then an agenda and invitation were circulated by the coordinator. Notes were kept during the meeting and then the meeting minutes were circulated by the coordinator. It should be noted that in addition to these official meetings there was constant communication between the two groups (usually via phone or email) to go over different aspects of the project. This was especially true when the two teams collaborated closely for the writing and participation in two funding proposals (one national and one EU).

2.2 Meetings

There were a total of five (5) consortium meetings with the meeting minutes given in the Appendix. Two physical ones, taking place at GOC and three virtual ones.

• 4/5/2023. Kickoff meeting. Physical meeting hosted at GOC. This was the beginning of the project and the goal of the meeting was to go over the project, (work packages, deliverables, outputs and impact) and coordinate and plan the next nine months of the project. This was to get everyone on the same page.

- 8/6/2023. Second meeting (virtual). The goal was to discuss the scientific results published by GOC and the way to use synthetic data to recreate the results generated with the real data.
- 3/1/2024. Third meeting (virtual). The purpose of the meeting was to prepare for the end of the project and therefore we started by reviewing the deliverables, project objectives, the final workshop and dissemination event.
- 8/1/2024. Fourth meeting (virtual). The goal was to discuss how to maximize the impact of the project using the synthetic data generated through the project. Three new synthetic data were generated (using three different methods) and it was decided to use those in blind tests to compare their conclusions versus the conclusions from the real data.
- 30/1/2024. Fifth consortium meeting. Physical meeting hosted at GOC. This was the end of the project, and the goal of the meeting was to review the deliverables and prepare for the final reporting and closing of the project (31/1/2024).

3. Conclusions

The consortium was able to coordinate its activities through open communication and through official consortium meetings. During the five consortium meetings the teams were able to coordinate the activities and deliverables of the project.

4. Acknowledgement








The project is implemented under the programme of social cohesion "THALIA 2021-2027" cofunded by the European Union, through Research and Innovation Foundation.

APPENDIX CONSORTIUM MEETINGS





AVATAR

Accelerating Innovation through data sharing data with no privacy concerns

Project: CONCEPT/0722/0019

Title of the Meeting: Kick-off Meeting

Task Number: T1.2

Title of Task: Management Meetings

Dates of the Meeting: 4/5/2023, 11:00 am

Institution Organizer of the Meeting: EUNDO

Meeting Place: German Oncology Center

Author of the Document: Charalambos Anastassiou

Institution: EUNDO

Publication Date: 15/05/2023



MEETING MINUTES

The meeting started with a welcome and presentation (Appendix) by the coordinator of the project, Charalambos Anastassiou (CA). There was an overview of the project, its goals and its administration (WP1), then there was an overview of dissemination and communication (WP). Then Andreas Livera presented the algorithms for WP3 followed with a discussion on validation (WP4). Some of the key points for each WP are given below.

<u>WP1.</u> Management will be handled by CA and there will be close coordination with Kristis Vevis (KV). CA will issue branding, templates along with the official acknowledgement for the project. The chronological list of to do list and deliverables will be kept and updated by CA and shared with the whole group. We will have monthly virtual meetings that CA will organize. Live meetings will be every 3 months.

<u>WP2.</u> There will be a press release for the project. It will be written by EUNDO and shared with GOC who will share through linkedin and facebook. The dissemination and communication plan was also discussed during the meeting as it is due by 31/5/2023. For some conferences that would be appropriate there is not enough time to complete the research and submit the abstract. It was decided to engage policy makers and key stakeholders in the area of data privacy especially in healthcare. Those would be: 1. The national eHealth Authority 2. Cyprus National Bioethics Committee. The engagement is to occur towards the end of the project (December 2023) so that we can show results.

<u>WP3.</u> AL discussed his approach. He will start with extensive literature search in order to see the latest available to be used for the project.

<u>WP4.</u> For the validation it was discussed that there are two main objectives for the synthetic data. The first one being utility. To demonstrate that the synthetic data can be used to draw realistic conclusions. The second being privacy. For the first objective we discussed upcoming published work of GOC with French collaborators (writing ML algorithms). GOC gave access to these data (anonymised) to EUNDO that will generate Synthetic Data. Those synthetic data can be given back to the same French collaborators that can run their analysis and obtain the updated conclusions (such as in the upcoming paper).



AGENDA

Main Objective:

Being the kickoff meeting of the project it is important we start strong. It is very important to have open and honest discussion so that only the most effective activities/methods are chosen for the project.

Main tasks of the meeting:

- Introduction of the teams, of the project and its administration.
- Agree on next steps, the next meeting and the action items.

PARTICIPANTS

Name	Institution
Charalambos Anastassiou	EUNDO LTD (EUN)
Andreas Livera	EUNDO LTD (EUN)
Kristis Vevis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Yiannis Roussakis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantina Cloconi	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantinos Zamboglou	LINAC PET SCAN OPCO, German Oncology Centre (GOC)



11:00	EUN : Welcome remarks by project coordinator and overview of the project <i>Charalambos Anastassiou</i>
10:05	EUN: WP1 overview: Management and Coordination Charalambos Anastassiou
10:15	EUN: WP2 overview: Dissemination and Exploitation Charalambos Anastassiou
11:25	EUN, WP3 Algorithm Development. Andreas Livera
11:35	EUN, WP4 Validation of privacy. Discussion with GOC Andreas Livera
11:45	Discussion and decisions for the next actions of the project. Any open issues.
	Charalambos Anastassiou

Acknowledgement













The project is implemented under the programme of social cohesion "THALIA 2021-2027" cofunded by the European Union, through Research and Innovation Foundation



Introduction to the project

Kickoff Meeting, May 04, 2023
At German Oncology Centre, Limassol Cyprus
By Dr. Charalambos Anastasiou (EUNDO)



Overview of the project

• Start: 01/05/2023

End: 31/1/2025

• Budget: €49,770. Funded €39815.8

• 4 Workpackages, 7 Deliverables, 8 Milestones

Work packages






Figure 1. WP inter-relations and workflow.

AVATAR Data you can share

Durations (lets stick to them)

B 4.5 Time Frame

Indicate the duration of each Work Package and the timing of submission of the Progress Reports.

Work Package Number / Title		DURATION (Months)								
	1	2	3	4	5	6	7	8	9	
WP1. Project Management										
WP2. Dissemination and Exploitation Activities										
WP3.Synthetic data algorithm development and securing of real healthcare data for validation										
WP4.Validation of the privacy and utility of the synthetic data										
Progress Reports Submitted to RIF										



WP1: Management tools

- Physical Meetings every three months
- Virtual Meetings: Every month <1h.
- Internal communication for all of us.
- Excel Sheet (updated by Pambos for keeping track of our progress).
- Deliverables template (to be sent out by Pambos)
- Overview of the final report



Upcoming Deliverables/MS

Del/MS	Deliverable	Туре	Classification	Due Date
D3	Dissemination and Communication Plan (DCP)	Report	Public	31/5/2023
MS1	Kick-off meeting			31/5/2023
MS2	Project press release			31/5/2023
MS4	Project Website and social media			30/6/2023



WP2:Lets discuss

- Press release (soon)
- Long term vision beyond the project
- Publication
- Other dissemination activities that we can participate. Reasonable as the project is only 9 months

Acknowledgment














The project is implemented under the programme of social cohesion "THALIA 2021-2027" co-funded by the European Union, through Research and Innovation Foundation

Loussalti SIGNATURE 415/2023 04/05/23 04/05/23 04/05/23 04 05 23 DATE 04/05/23 German Oncology Center German Oncology Center Verman Orcology anter Project: AVATAR, concept/0722/0019 EUNDO LTD INSTITUTION EUNDO LTD)Location: German Oncology Center TITLE . Kickelf Meeting Charalambos Anastas iou Dute: 4/5/2023 Viannis Roussakis Hindures, Liveria Constantina Wowi Kriskis Vevis NANT





AVATAR

Accelerating Innovation through data sharing data with no privacy concerns

Project: CONCEPT/0722/0019



Title of the Meeting: Second Meeting (Virtual)

Task Number: T1.2

Title of Task: Management Meetings **Dates of the Meeting:** 8/6/2023, 15:00

Institution Organizer of the Meeting: EUNDO

Meeting Place: Online. Google meet

Author of the Document: Charalambos Anastassiou

Institution: EUNDO

Publication Date: 9/06/2023


MEETING MINUTES

We started with a brief overview of the project, reviewed the press release discussed any pending issues (not many as the project just stated and is progressing normally). The main issue of the meeting was more of a scientific discussion on the recently published paper by the GOC (Scharl, Sophia, Constantinos Zamboglou, Iosif Strouthos, Andrea Farolfi, Francesca Serani, Helena Lanzafame, Alessio Giuseppe Morganti et al. "Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence-results of a retrospective study." Radiotherapy and Oncology 184 (2023): 109678". The GOC team briefly presented the results and the research that was done for that publication.


The above-mentioned paper used data from 1222 oncology patients from 11 medical centers. One of the main outcomes of that paper is a nomogram for cure after salvage radiotherapy for prostate cancer (shown below). During the meeting it was decided to use those anonymized data by EUNDO to generate synthetic data and in the future try to recreate that nomogram. The main parameters (that are clinically relevant) were chosen for the investigation and generation of synthetic data.


Main Decisions:

- Develop the numerical synthetic models based on the data from the published paper so
 that the conclusions can be compared. That will validate the clinical relevance between
 them.
- Organize a meeting with the privacy and head of IT at GOC Mr Costas Giorgallas in order to better understand privacy issues from a healthcare facility perspective.










ADT indicates androgen deprivation therapy; ISUP, International Society of Urological Pathology; PET, positron emission tomography; PSA, prostate-specific antigen; and R status, resection status. Dose to the fossa is given in equivalent dose 2 Gy (EQD2, $\alpha/\beta=1.6$ Gy). SI conversion factor: To convert PSA to to micrograms per liter, multiply by 1.0.

Invitation Picture





AGENDA

Main Objective:

As was discussed during the kickoff meeting the next steps for the project are to review recently published paper (doi:10.1001/jamanetworkopen.2023.14748) and discuss how to use the data from that paper for the generation of synthetic data.

PARTICIPANTS

Name	Institution
Charalambos Anastassiou	EUNDO LTD (EUN)
Andreas Livera	EUNDO LTD (EUN)
Kristis Vevis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Yiannis Roussakis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantina Cloconi	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantinos Zamboglou	LINAC PET SCAN OPCO, German Oncology Centre (GOC)

15:00	EUN : Welcome remarks by project coordinator and overview of the deliverables and actions up to now for WP1 and WP2 <i>Charalambos Anastassiou</i>
15:10	EUN, WP3 Algorithm Development.
	Andreas Livera
11:15	EUN, WP4 Validation of privacy. Discussion with GOC
11.13	Andreas Livera
15:25	Discussion and decisions for the next actions of the project. Any open issues.
	Charalambos Anastassiou



Acknowledgement










The project is implemented under the programme of social cohesion "THALIA 2021-2027" cofunded by the European Union





AVATAR

Accelerating Innovation through data sharing data with no privacy concerns

Project: CONCEPT/0722/0019

Title of the Meeting: Kick-off Meeting

Task Number: T1.2

Title of Task: Management Meetings

Dates of the Meeting: 3/1/2024, 10:00 am

Institution Organizer of the Meeting: EUNDO

Meeting Place: Virtual Meeting

Author of the Document: Charalambos Anastassiou

Institution: EUNDO

Publication Date: 04/01/2024



MEETING MINUTES

The purpose of the meeting was to prepare for the end of the project and therefore we started by reviewing the deliverables, project objectives, the final workshop and dissemination event.

Project Overview:

Start: 01/05/2023

End: 31/01/2024

Lets review deliverables

D3	WP2	Dissemination and	Report	Public	31/5/2023	
		Communication Plan (DCP)				Done
MS1	WP1	Kick-off meeting			31/5/2023	Done
MS2	WP2	Project press release			31/5/2023	Done
MS4	WP2	Project Website and social media			30/6/2023	Done
MS5	WP3	Real-world data gathered			31/7/2023	Done
D4	WP2	Submission of Request for the Services of the Central Knowledge Transfer Office (KTO)	Other	Confidential	31/8/2023	Done
D6	WP3	Synthetic data generator	Report	Confidential	30/9/2023	Done
MS7	WP4	Evaluation metrics list			30/10/202	
		formulated			3	Done
D1	WP1	Consortium meetings minutes	Report	Public	31/1/2024	Done
D2	WP1	Final Progress Report	Report	Confidential	31/1/2024	Pendin g
D5	WP2	IPR Management and Exploitation Plan	Report	Confidential	31/1/2024	Pendin g
D7	WP4	Validation of the synthetic data generator results	Report	Public	31/1/2024	Done
MS3	WP2	Final dissemination event at GOC			31/1/2024	Pendin g
MS8	WP4	Synthetic data generator validated			31/1/2024	Pendin g
MS6	WP3	Synthetic data generator ready			31/09/202 3	Pendin g



Financials

		Direct Cos	its	Other 9	Simplified Costs								
	Personnel	Rate	PersonMonths	Rate	Other Simplified amount	Budget	Aid Intensity	Max Funding	Requersted Funding	Project Duration	New positions	Pre-financing	At Completion of project
EUNDO	26,465€	3,950 €	6.7	40%	10,586 €	37,051€	0.8	29,640.80€	29,640.80 €	9	1	20,748.56 €	8,892.24€
LINAC	9,085 €	3,950€	2.3	40%	3,634 €	12,719€	0.8	10,175.20€	10,175.00€			7,122.50€	3,052.50€
Total	35,550€		9		14,220 €	49,770 €	0.8	39,816.00€	39,815.80 €			27,871.06 €	11,944.74 €

The meeting started with a welcome by the coordinator of the project, Charalambos Anastassiou (CA). There was an overview of the project, its goals and its administration (WP1), then there was an overview of dissemination and communication (WP). Then Andreas Livera presented the algorithms for WP3 followed with a discussion on validation (WP4). Some of the key points for each WP are given below.

Let's review the objectives of the project:

To promote innovation in Cyprus: In AVATAR we will set the foundations for technology development by creating privacy preserving synthetic health data. We will demonstrate and validate this principle in a lab setting, bringing this work to a technology readiness level (TRL) of 4 (TRL 4 - technology validated in lab). As a matter of focus, this work will start with cancer (and more specifically prostate cancer), but this methodology can be extended for a wide variety of diseases that can have an impact on healthcare technology and policy decision. As part of the project, we will seek outside private funding such as venture capital (VC) and angel investors to proceed with the evaluation, demonstration and transfer phases (TRL 5-8) after the completion of the project, aiming to finally commercialize this proof of concept (reaching a TRL 9).

<u>To create national networks of collaboration focused on healthcare:</u> The AVATAR project will bring together the following key actors that are crucial for healthcare innovation:

- o *Engineering* and data scientists for the development of AI algorithms and data processing.
- Medical schools and private hospitals for providing the data and ensuring that the methods
 are compatible with privacy protocols. This is an important step in the validation of the
 methodology developed by engineering.
- o *Private funding* and the entrepreneurship community for providing the funds, mentoring and connections for the commercialization of this proof of concept. The discussions and engagement with the private funding and entrepreneurship community will be done during AVATAR to ensure the continuation of this project (to reach a higher TRL) and the alignment with the market needs. The demonstration and commercialization activities will commence after the completion of AVATAR.

<u>WP1.</u> Management will be handled by CA and there will be close coordination with Kristis Vevis (KV). CA will issue branding, templates along with the official acknowledgement for the project. The chronological list of to do list and deliverables will be kept and updated by CA and shared with the whole group. We will have monthly virtual meetings that CA will organize. Live meetings will be every 3 months.

(December 2023) so that we can show results.



<u>WP2.</u> There will be a press release for the project. It will be written by EUNDO and shared with GOC who will share through linkedin and facebook. The dissemination and communication plan was also discussed during the meeting as it is due by 31/5/2023. For some conferences that would be appropriate there is not enough time to complete the research and submit the abstract. It was decided to engage policy makers and key stakeholders in the area of data privacy especially in healthcare. Those would be: 1. The national eHealth Authority 2. Cyprus National Bioethics Committee. The engagement is to occur towards the end of the project

<u>WP3.</u> AL discussed his approach. He will start with extensive literature search in order to see the latest available to be used for the project.


<u>WP4.</u> For the validation it was discussed that there are two main objectives for the synthetic data. The first one being utility. To demonstrate that the synthetic data can be used to draw realistic conclusions. The second being privacy. For the first objective we discussed upcoming published work of GOC with French collaborators (writing ML algorithms). GOC gave access to these data (anonymised) to EUNDO that will generate Synthetic Data. Those synthetic data can be given back to the same French collaborators that can run their analysis and obtain the updated conclusions (such as in the upcoming paper).

Main Decisions:

- Arrange for the final workshop and dissemination event to take place at the German Oncology Center to be done on the last week of January.
- Invite to the final dissemination event the Office of the Commissioner for Personal Data Protection.



Invitation Picture





Picture from the Meeting



AGENDA

Meeting Venue

AVATAR virtual meeting Wednesday, January 3 · 10:00 – 11:00am

Time zone: Asia/Nicosia Google Meet joining info

Video call link: https://meet.google.com/ufo-zreb-fmn

Main Objective:


This is a preparatory meeting for the closing of the project.

Main tasks of the meeting:

• Review the final tasks for the project and plan to address any missing items.

PARTICIPANTS

Name	Institution
Charalambos Anastassiou	EUNDO LTD (EUN)
Andreas Livera	EUNDO LTD (EUN)
Kristis Vevis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Yiannis Roussakis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantina Cloconi	LINAC PET SCAN OPCO, German Oncology Centre (GOC)





Constantinos Zamboglou	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
------------------------	---



10:00	EUN : Welcome remarks by project coordinator and overview of the project <i>Charalambos Anastassiou</i>
10:05	EUN: WP1 overview: Management and Coordination Charalambos Anastassiou
10:15	EUN: WP2 overview: Dissemination and Exploitation Charalambos Anastassiou
11:25	EUN, WP3 Algorithm Development. Andreas Livera
11:35	EUN, WP4 Validation of privacy. Discussion with GOC Andreas Livera
11:45	Discussion and decisions for the next actions of the project. Any open issues.
	Charalambos Anastassiou

Acknowledgement












The project is implemented under the programme of social cohesion "THALIA 2021-2027" cofunded by the European Union, through Research and Innovation Foundation





AVATAR

Accelerating Innovation through data sharing data with no privacy concerns

Project: CONCEPT/0722/0019

Title of the Meeting: Kick-off Meeting

Task Number: T1.2

Title of Task: Management Meetings

Dates of the Meeting: 8/01/2024, 02:00 pm

Institution Organizer of the Meeting: EUNDO

Meeting Place: Virtual Meeting

Author of the Document: Charalambos Anastassiou

Institution: EUNDO

Publication Date: 8/01/2024




MEETING MINUTES

The main purpose of this meeting was to review the synthetic data generation by Andreas Livera (AL) and discuss the next steps with the data scientist from GOC, Andreas Christoforou (AC). AL showed the three separate ways to generate synthetic data and the consortium discussed ways to increase the impact of these findings for the project. It was decided that the best way would be to try and publish both the methodology and the utility of the synthetic data. To do this Constantinos Zamboglou (CZ) suggested giving three data sets (blind, without revealing what set is from what method to avoid bias) to AC and let him run some tests on what the most useful set is. That would lead to a publication (either peer review or conference).

Main Decisions:


AL to provide the three data sets in a blind test for AC. AC to analyse the statistical
properties and compare to the real data set (published results).

Invitation Picture





Picture from the Meeting



AGENDA

Meeting Venue

AVATAR virtual meeting Wednesday, January $8 \cdot 02:00 - 03:00 \text{ pm}$

Time zone: Asia/Nicosia Google Meet joining info

Video call link: https://meet.google.com/ufo-zreb-fmn



Main Objective:

Review ways to maximize the impact of the results obtained through the project.

Main tasks of the meeting:

• Review the synthetic data generation

PARTICIPANTS

Name	Institution
Charalambos Anastassiou	EUNDO LTD (EUN)
Andreas Livera	EUNDO LTD (EUN)
Andreas Christoforou	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Yiannis Roussakis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantina Cloconi	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantinos Zamboglou	LINAC PET SCAN OPCO, German Oncology Centre (GOC)



2:00	EUN : Welcome remarks by project coordinator <i>Charalambos Anastassiou</i>
2:05	EUN: Presentation of the algorithms and synthetic data Andreas Livera
2:15	EUN : Discussion and decisions for the next actions of the project. Closing of the meeting Charalambos Anastassiou
2:30	Closing of the meeting

Acknowledgement










The project is implemented under the programme of social cohesion "THALIA 2021-2027" cofunded by the European Union, through Research and Innovation Foundation





AVATAR

Accelerating Innovation through data sharing data with no privacy concerns

Project: CONCEPT/0722/0019

Title of the Meeting: Fifth Consortium Meeting

Task Number: T1.2

Title of Task: Management Meetings

Dates of the Meeting: 30/01/2024, 11:30 am

Institution Organizer of the Meeting: EUNDO

Meeting Place: Virtual Meeting

Author of the Document: Charalambos Anastassiou

Institution: EUNDO

Publication Date: 31/01/2024



MEETING MINUTES

In order to coordinate the final reporting of the project Charalambos Anastassiou (CA) went through the final report status in order to understand what is missing and what needs to be done in the next few weeks. The main topics of discussion were:

- D2 Final Progress Report (Report, M9). Final technical and financial reporting to the funding agency. No problem on the Technical but need to work on the financial part as well. Kri
- Task 2.1. Press releases and media engagement [M1-M9]. Done.
- Task 2.2. Project Website social media pages (not charged to the project) [M1]. Done
- <u>Task 2.3.</u> Dissemination and Communication. We have the plan. We have decided on a publication for both the methodology and the comparison results
- <u>Task 2.4.</u> Private funding effort. Applied to Digitalgendency as private funding and also applied for public funding (national co-develop) and EU (IHI).
- <u>Task 2.5.</u> IPR Management and Exploitation activities [M1-M9] Lead. Met with CKTO and will be following up on their recommendations.
- MS2 Project press release (M1). DONE
- MS3 Final dissemination event at GOC (M9). DONE
- MS4 Project Website and social media (M2). DONE. Would be good to have some more visits, more links to the Facebook.
- D3 Dissemination and Communication Plan (DCP) (Report, M1). Plan for engagement with the entrepreneurial community, demonstrations, final event, peer-review journals, conferences, social and traditional media to engage. DONE
- D4 Submission of Request for the Services of the Central Knowledge Transfer Office (KTO) (Other, M4). DONE We have the two reports.
- D5 IPR Management and Exploitation Plan (Report, M9). Plan for IPR management and exploitation beyond the completion of the project. To be completed.
- Task 4.1. Development of evaluation metrics list [M5-M6] Lead: EUNDO. DONE
- <u>Task 4.2</u>. Performance Evaluation [M6-M9] Lead: EUNDO. Task 4.2 concerns with the validation of the generated data using evaluation metrics. The artificially generated synthetic data will be tested for privacy, resemblance and utility. The metrics (defined in Task 4.1) will be used
- Privacy evaluation still needs some work.

Main Decisions:

• Start working on the report. EUNDO and GOC will be coordinating on the technical and financial report.

Signup Sheet



T1.2. Final Consortium Meeting, 30 JANUARY 2024




AVATAR

Accelerating Innovation through data sharing data with no privacy concerns
Project: CONCEPT/0722/0019

EUNDO LTD (EUN)	A
EUNDO ETD (EUN)	(Charles)
EUNDO LTD (EUN)	ALA .
LINAC PET SCAN OPCO, German Oncology Centre (GOC)	With E
German Oncology Centre (GOC)	Houssales
German Oncology Centre (GOC)	
German Oncology Centre (GOC)	Con the second
u h	
	0
]	LINAC PET SCAN OPCO, German Oncology Centre (GOC)



Picture from the Meeting



AGENDA



Meeting Venue

AVATAR physical meeting at GOC January 30, 11:30 – 12:30 am

Main Objective:

Discuss the close out of the project and the next steps.

Main tasks of the meeting:

- Review all deliverables, Milestones, outputs, achievements and exploitation of the results of the project
- Discuss the final report (technical and financial) and the next expected steps for the successful closeout of the project.

PARTICIPANTS

Name	Institution
Charalambos Anastassiou	EUNDO LTD (EUN)
Andreas Livera	EUNDO LTD (EUN)
Kristis Vevis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Yiannis Roussakis	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Andreas Christoforou	LINAC PET SCAN OPCO, German Oncology Centre (GOC)
Constantinos Zamboglou	LINAC PET SCAN OPCO, German Oncology Centre (GOC)

11:30	EUN: Welcome remarks by project coordinator and overview of the deliverables and actions up to now for WP1 and WP2 Charalambos Anastassiou
11:45	EUN, WP3 Algorithm Development.
	Andreas Livera
12:00	EUN, WP4 Validation of privacy and utility. Andreas Livera
12:30	Discussion and decisions for the closeout of the project. Any open
	issues.
	Charalambos Anastassiou

T1.2. Fifth Consortium Meeting, 30 January 2024 Meeting Minutes



Acknowledgement







The project is implemented under the programme of social cohesion "THALIA 2021-2027" cofunded by the European Union, through Research and Innovation Foundation